Chemotherapy and Drug Information
Combining chemotherapy with new drugs that target a protein that helps cancer cells withstand chemotherapy could improve treatment.
Chemotherapy administered to patients with cancer who are near death does not improve quality of life.
Research indicates a connection between chemo-related cognitive function decline and molecular immune biomarkers, genetic aging, and neurotransmitter markers.
The impact of 5-hydroxytryptamine-receptor antagonists on chemotherapy treatment adherence, treatment delay, and nausea and vomiting
[Cancer Management and Research] This research examines the incidence of chemotherapy-induced nausea/vomiting (CINV) and treatment delay among patients receiving palonosetron versus other 5-hydroxytryptamine receptor antagonist (5-HT3 RA) antiemetics.
Overweight or obese patients with ovarian cancer are typically given lower per-pound chemotherapy doses to reduce toxic side effects, which could impact their survival chances.
New companion diagnostic kit can identify candidates
Is there evidence to support adding potassium magnesium and mannitol to the hydration regimens for cisplatin?
New guidelines released by the American College of Cardiology (ACC) and the American Heart Association (AHA) would have 13 million more Americans taking the cholesterol drugs, experts say.
The stress hormones often used to treat the side effects of chemotherapy could have the side effect of making effective cancer drugs fail sooner in some women with breast cancer, according to new research.
A three-drug combination antiemetic therapy including aprepitant or fosaprepitant improved the prevention rate of nausea and vomiting.
Stat Consult Slideshows
This slideshow reviews fluorouracil (5-FU), indicated for palliative treatment of breast cancer, colorectal cancer, gastric cancer, and carcinoma of the pancreas; also adjuvant treatment of colorectal cancer.
This slideshow reviews netupitant/palonosetron (Akynzeo), indicated for prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy.
This slideshow reviews bevacizumab (Avastin), indicated for cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel and topotecan in persistent, recurrent, or metastatic disease.
To view all content in our Stat Consult section, please click here.
- Multiple myeloma uses "wolf in sheep's clothing" tactic to avoid immune response in bone
- Comparison of zoledronic acid dosing schedules finds less frequent schedule noninferior
- HPV16 detection after oropharyngeal cancer treatment may increase risk for recurrence
- Delayed referrals, diagnoses undermine cancer patients' faith in health care system
- Alcohol Consumption Linked with Less Disability in Chronic Pain
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|